Corona Remedies IPO Analyzed
Key Points
- Corona Remedies IPO opens December 8, 2025, for 6 weeks.
- Investors can buy up to 6.2 million shares – no new shares.
- Price range: ₹1,008 to ₹1,062 per share. Minimum 14 shares.
- Expected debut: December 15, 2025.
- Risks include reliance on specific products and markets.
- Regulatory compliance is crucial for the company’s operation.
Corona Remedies is planning to sell shares to the public for the first time. This is called an IPO, and it’s happening on December 8, 2025. Investors can buy up to 6.2 million shares, but no new shares will be created. It’s like buying existing shares from the company itself.
The company wants to raise ₹655.37 crore. Investors can buy shares for between ₹1,008 and ₹1,062 each. You’ll need to buy at least 14 shares to make a “lot”. The company expects to start trading on December 15, 2025, if the sale goes well.
However, there are some things to think about before you invest. The company makes most of its money from just a few products, and it only sells its products in India. If these products don’t sell well, or if competition gets tougher, the company could have problems.
The company also relies on outside suppliers for its ingredients. If these suppliers have problems, it could slow down production. Finally, the company needs to follow lots of rules and regulations to operate legally, and failing to do so could cause issues.
The grey market price (an unofficial market) suggests investors are excited about the IPO. Shares were trading at ₹1,392 on December 4, 2025, a premium of 31% over the upper price. This shows strong demand.
Bigshare Services is the company responsible for making sure the sale happens smoothly. JM Financial, IIFL Capital Services, and Kotak Mahindra Capital Company are helping the company manage the sale.
Remember, investing in the stock market carries risk.
Investing in IPOs can be unpredictable, so do thorough research before making any decisions.
